Please login to the form below

Not currently logged in
Email:
Password:

atopic dermatitis

This page shows the latest atopic dermatitis news and features for those working in and with pharma, biotech and healthcare.

AbbVie’s upadacitinib aces phase III trial

AbbVie’s upadacitinib aces phase III trial

even climb as high as $5bn at peak if it also shows its worth in follow-up indications like psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis and atopic dermatitis.

Latest news

More from news
Approximately 5 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    Phase II MAb to block IL-13 for treatment of atopic dermatitis.

  • Deal Watch September 2016 Deal Watch September 2016

    as well as other autoimmune disorders plus VTP-38543 for atopic dermatitis.

  • Deal Watch July 2016 Deal Watch July 2016

    AstraZeneca is developing tralokinumab for severe asthma, where it is in phase III development, and has recently completed a phase IIb study in patients with atopic dermatitis.

  • Allergies and asthma Allergies and asthma

    Early prevention is recommended. Allergic diseases (eg food allergies, rhinitis, asthma, atopic dermatitis) usually start in childhood but can develop at any age. ... of the hypo-allergenic milk formula on cow's milk allergy and atopic dermatitis (AD).

  • Deal Watch May 2016 Deal Watch May 2016

    Paying a 55% premium at $99.25 per share, the acquisition brings crisaborole, a topical PDE4 inhibitor for mild to moderate atopic dermatitis (eczema) with estimated peak sales of $2bn.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics